Zifan Lu

Prof. Zifan Lu


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SWShan Wang
Shan Wang
XWXiuchao Wang
Xiuchao Wang
ZYZichen Ye
Zichen Ye
CXChengming Xu
Chengming Xu
MZMing Zhang
Ming Zhang
ZLZifan Lu
Zifan Lu

1 January 2010 in Gastroenterology
Verified
Journal Article
Open access
PDF file
GYGuodong Yang
Guodong Yang
HFHaiyan Fu
Haiyan Fu
JZJie Zhang
Jie Zhang
XLXiaozhao Lu
Xiaozhao Lu
FYFang Yu
Fang Yu
ZLZifan Lu
Zifan Lu
Background & Aims Colon cancer is one of the best understood neoplasms from a genetic perspective, yet it remains the second most common cause of cancer-related death. Post-transcriptional regulation mediated by RNA-binding proteins or microRNAs coordinately targets multiple genes, holding promise involved in colon cancer initiation and development. Here we studied the role of RNA-binding protein quaking (QKI) in colon cancer. Methods We observed the expression pattern of QKI in normal colon and colon cancers through reverse-transcription polymerase chain reaction and Western blot. Bisulfite sequencing and methylation-specific PCR were applied for QKI promoter methylation analysis. We used enterocyte differentiation markers and soft agar assay to test the role of QKI in colon differentiation and colon cancer development. 3′ Untranslated region (UTR) reporter assay and RNA-immunoprecipitation were used to confirm the interaction between QKI and β-catenin or p27. Results QKI is significantly down-regulated and even absent in some colon cancers, which is at least partially because of the promoter hypermethylation. Forced expression of QKI in the colon cancer cells increased the expression of enterocyte differentiation marker intestinal alkaline phosphatase and lactase, together with the enhancement of p27Kip1 protein level, and membrane localized β-catenin. Finally, QKI overexpression reduced the proliferation and tumorigenesis ability. Conclusions Our study establishes that QKI functions as a principal regulator in the differentiation of colon epithelium and a suppressor of carcinogenesis through coordinately targeting multiple genes associated with cell growth and differentiation, whose deregulation by methylation is involved in colon cancer onset and progress.

1 October 2013 in Endocrinology
Verified
Journal Article
Open access
PDF file
XCXiaorui Cao
Xiaorui Cao
HLHuan Li
Huan Li
HTHuiren Tao
Huiren Tao
NWNing Wu
Ning Wu
LYLifeng Yu
Lifeng Yu
QZQingsheng Zhu
Qingsheng Zhu
Metformin exhibits diverse protective effects against diabetic complications, such as bone loss. Here, we investigated the effect of metformin on vascular calcification, another type 2 diabetes complication. In female rat aortic smooth muscle cells (RASMCs), we observed that metformin significantly alleviated β-glycerophosphate-induced Ca deposition and alkaline phosphatase activity, corresponding with reduced expression of some specific genes in osteoblast-like cells, including Runx2 and bone morphogenetic protein-2, and positive effects on α-actin expression, a specific marker of smooth muscle cells. Mechanistic analysis showed that phosphorylation levels of both AMP-activated protein kinase (AMPK) and endothelial nitric oxide synthase (eNOS) were increased with NO overproduction. After inhibition of either AMPK or eNOS with the pharmacologic inhibitors, compound C or Nω-Nitro-L-arginine methyl ester, NO production was lowered and metformin-meditated vascular protection against β-glycerophosphate-induced Ca deposition was removed. Our results support that metformin prevents vascular calcification via AMPK-eNOS-NO pathway.

1 August 2016 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
WMWei Ming
Wei Ming
GLGan Lu
Gan Lu
SXSha Xin
Sha Xin
LHLu Huanyu
Lu Huanyu
JYJiang Yinghao
Jiang Yinghao
ZLZifan Lu
Zifan Lu

1 December 2017 in Molecular Immunology
Verified
Journal Article
Closed access
DZDongsheng Zhai
Dongsheng Zhai
ZYZichen Ye
Zichen Ye
YJYinghao Jiang
Yinghao Jiang
CXChengming Xu
Chengming Xu
BRBanjun Ruan
Banjun Ruan
ZLZifan Lu
Zifan Lu

25 July 2013 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
FWFeng Wei
Feng Wei
YLYan Liu
Yan Liu
YGYanhai Guo
Yanhai Guo
XAxiang an
xiang an
GWGuangyi Wang
Guangyi Wang
ZLZifan Lu
Zifan Lu
Background: Radiation exerts direct antitumor effects and is widely used in clinics, but the efficacy is severely compromised by tumor resistance. Therefore uncovering the mechanism of radioresistance might promote the development of new strategies to overcome radioresistance by manipulating activity of the key molecules. Methods: Immunohistochemistry were used to find whether mTOR were over-activated in radioresistant patients’ biopsies. Then Western blot, real-time PCR and transfection were used to find whether radiotherapy regulates the expression and activity of mTOR by modulating its targeting microRNA in human pancreatic cancer cell lines PANC-1, Capan-2 and BxPC-3. Finally efficacy of radiation combined with mTOR dual inhibitor AZD8055 was assessed in vitro and in vivo. Results: Ionizing radiation promoted mTOR expression and activation in pancreatic cancer cells through reducing miR-99b expression, which negatively regulated mTOR. Novel mTOR inhibitor, AZD8055 (10 nM, 100 nM, 500 nM) synergistically promoted radiation (0–10 Gy) induced cell growth inhibition and apoptosis. In human pancreatic cancer xenografts, fractionated radiation combined with AZD8055 treatment further increased the anti-tumor effect, the tumor volume was shrinked to 278 mm3 after combination treatment for 3 weeks compared with single radiation (678 mm3) or AZD8055 (708 mm3) treatment (P < 0.01). Conclusions: Our data provide a rationale for overcoming radio-resistance by combined with mTOR inhibitor AZD8055 in pancreatic cancer therapy.